Concepedia

Erik Buntinx

EB

Statistics

Publications

8

Citations

514

H-Index

8

Active since

2008

Affiliations

Erasmus Hospital(Current)

University of Ferrara

University of the East Ramon Magsaysay Memorial Medical Center

GlaxoSmithKline (Belgium)

Catholic University of Korea

Erik Buntinx is an author at Erasmus Hospital specializing in veterinary medicine, vaccine immunology, and vaccination.

Publications per year

2008–2024

8

Publications

8

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Michael G. Ison, Alberto Papi, Eugene Athan et al. · Clinical Infectious Diseases · 2024 · 162 citations · Full text

, , +17

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Lulu Bravo, Igor Smolenov, Htay Htay Han et al. · The Lancet · 2022 · 113 citations · Full text

, , +16

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

, , +14

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 53 citations

, , +16

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers et al. · Clinical Infectious Diseases · 2023 · 52 citations · Full text

, , +17

1–5 of 8